drug
ciltacabtagene autoleucel
Marketedupdated 7mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ciltacabtagene autoleucel
News(10)
- Pfizer leaps into ‘in vivo’ CAR-T with latest China dealThe potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.biopharma_dive · 2d ago
- China has a clear shot to 2030 goals, though economic, cultural barriers remainTo grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.biospace · 10d ago
- Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturingThe BioSpace 40 Under 40 honoree helped steer Forge’s sale to Ajinomoto. Now, Samantha Piteri-Molina sees opportunities in AI-driven analytics and Ohio’s gene therapy ecosystem—with a responsibilit…biospace · 14d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 17d ago
- Most new drugs are still too costly at launch, ICER saysA new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.biopharma_dive · 1mo ago
- Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitPlus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…endpoints · 1mo ago
- J&J, Legend tout long-term survival benefits for Carvykti in multiple myelomaTen patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.biospace · 1mo ago
- Legend names new CEO as Carvykti competition grows; Vertex makes a flurry of moves→ Legend Biotech has tapped Novartis executive Ingrid Zhang as its new CEO at a time when the company is seeking its next act. The company’s shares {$LEGN} are down 50% ...endpoints · 2mo ago
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…fiercebiotech · 2mo ago
- Unlocking cell surface protein research with site-specific labelingApplications in flow cytometry, cell sorting, target validation, and therapeutic discoverybiospace · 2mo ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that